Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond

Critical Reviews in Clinical Laboratory Sciences

Volumn 53, Issue 6, 2016, Pages 409-430

  Xu, Xiaohong Ruby ^a,b,c   Zhang, Dan ^b,c   Oswald, Brigitta Elaine ^a,b,d   Carrim, Naadiya ^a,b,d   Wang, Xiaozhong ^b,e   Hou, Yan ^b,f   Zhang, Qing ^b,g   Lavalle, Christopher ^a,b   McKeown, Thomas ^b   Marshall, Alexandra H ^b   Ni, Heyu ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^d CANADIAN BLOOD SERVICES   (Canada)

^e NANCHANG UNIVERSITY   (China)

^f Jilin Provincial Center for Disease Control and Prevention   (China)

^g SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiogenesis; atherosclerosis; fibrinogen; fibronectin; inflammation; integrin; lymphatic vessel; metastasis; thrombocytopenia; venous thromboembolism

Indexed keywords

BETA3 INTEGRIN; FIBRINOGEN; FIBRONECTIN; LIGAND; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN; PROTEOME; SHEDDOME; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL WALL; CARCINOGENESIS; CELL ADHESION; CELL CYCLE ARREST; CELL GRANULE; CELL INTERACTION; CELL MIGRATION; CELL SURVIVAL; CELLULAR SECRETION; CLEARANCE; EXTRAVASATION; HEMOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LIPID METABOLISM; LYMPHANGIOGENESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE LIFESPAN; THROMBOCYTE STRUCTURE; THROMBOCYTOPOIESIS; THROMBOSIS; VASCULAR BIOLOGY; VENOUS THROMBOEMBOLISM; WOUND HEALING; THROMBOCYTOPENIA;

BLOOD PLATELETS; HEMOSTASIS; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84986563688     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408363.2016.1200008     Document Type: Review

References (348)

1. B.S.Coller Foreword:a brief history of ideas about platelets in health and disease. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013:xix–xliv
2. Y.Wang, M.Andrews, Y.Yang,. Platelets in thrombosis and hemostasis:old topic with new mechanisms. Cardiovasc Hematol Disord Drug Targets 2012;12:126–32
3. Z.M.Ruggeri Platelets in atherothrombosis. Nat Med 2002;8:1227–34
4. C.Li, J.Li, Y.Li,. Crosstalk between platelets and the immune system:old systems with new discoveries. Adv Hematol 2012;2012:384685
5. J.W.Semple, J.E.Italiano, JrJ.Freedman Platelets and the immune continuum. Nat Rev Immunol 2011;11:264–74
6. D.Siegel-Axel, K.Daub, P.Seizer,. Platelet lipoprotein interplay:trigger of foam cell formation and driver of atherosclerosis. Cardiovasc Res 2008;78:8–17
7. S.Lindemann, B.Kramer, P.Seizer, M.Gawaz Platelets, inflammation and atherosclerosis. J Thromb Haemost 2007;5:203–11
8. A.J.Murphy, N.Bijl, L.Yvan-Charvet,. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med 2013;19:586–94
9. P.R.Hess, D.R.Rawnsley, Z.Jakus,. Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life. J Clin Invest 2014;124:273–84
10. L.Navarro-Nunez, S.A.Langan, G.B.Nash, S.P.Watson The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost 2013;109:991–8
11. M.Osada, O.Inoue, G.Ding,. Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. J Biol Chem 2012;287:22241–52
12. B.H.Herzog, J.Fu, S.J.Wilson,. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature 2013;502:105–9
13. J.E.Italiano, Jr., J.L.Richardson, S.Patel-Hett,. Angiogenesis is regulated by a novel mechanism:pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111:1227–33
14. M.Chatterjee, Z.Huang, W.Zhang,. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 2011;117:3907–11
15. I.Yougbare, S.Lang, H.Yang,. Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest 2015;125:1545–56
16. M.Labelle, R.O.Hynes The initial hours of metastasis:the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012;2:1091–9
17. M.Labelle, S.Begum, R.O.Hynes Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA 2014;111:E3053–61
18. A.T.Franco, A.Corken, J.Ware Platelets at the interface of thrombosis, inflammation, and cancer. Blood 2015;126:582–8
19. J.H.Hartwig Chapter 8:the platelet cytoskeleton. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013:145–68
20. S.P.Jackson, W.S.Nesbitt, E.Westein Dynamics of platelet thrombus formation. J Thromb Haemost 2009;7:17–20
21. F.Nakamura, T.P.Stossel, J.H.Hartwig The filamins:organizers of cell structure and function. Cell Adh Migr 2011;5:160–9
22. H.Wang, K.W.Bang, V.S.Blanchette,. Phosphatidylserine exposure, microparticle formation and mitochondrial depolarisation in Glanzmann thrombasthenia platelets. Thromb Haemost 2014;111:1184–6
23. H.R.Roberts, M.Hoffman, D.M.Monroe A cell-based model of thrombin generation. Semin Thromb Hemost 2006;32:32–8
24. D.M.Monroe, M.Hoffman, H.R.Roberts Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381–9
25. W.Choi, Z.A.Karim, S.W.Whiteheart Protein expression in platelets from six species that differ in their open canalicular system. Platelets 2010;21:167–75
26. H.Heijnen, P.van der Sluijs Platelet secretory behaviour:as diverse as the granules or not? J Thromb Haemost 2015;13:2141–51
27. D.Jonnalagadda, L.T.Izu, S.W.Whiteheart Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood 2012;120:5209–16
28. Y.Wang, E.Vachon, J.Zhang,. Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. J Exp Med 2005;202:1587–97
29. J.K.Mountford, C.Petitjean, H.W.Putra,. The class II PI 3-kinase, PI3KC2α, links platelet internal membrane structure to shear-dependent adhesive function. Nat Commun 2015;6:6535
30. A.Reheman, P.Gross, H.Yang,. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 2005;3:875–83
31. Y.Wang, R.C.Gallant, H.Ni Extracellular matrix proteins in the regulation of thrombus formation. Curr Opin Hematol 2016;23:280–7
32. A.Reheman, S.Tasneem, H.Ni, C.P.Hayward Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thromb Res 2010;125:e177–83
33. P.Von Hundelshausen, F.Petersen, E.Brandt Platelet-derived chemokines in vascular biology. Thromb Haemost 2007;97:704–13
34. M.H.Klinger, W.Jelkmann Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22:913–22
35. B.F.Kraemer, R.A.Campbell, H.Schwertz,. Novel anti-bacterial activities of β-defensin 1 in human platelets:suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog 2011;7:e1002355
36. C.A.Gleissner, P.von Hundelshausen, K.Ley Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 2008;28:1920–7
37. R.R.Koenen, P.von Hundelshausen, I.V.Nesmelova,. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009;15:97–103
38. J.H.Morrissey, S.H.Choi, S.A.Smith Polyphosphate:an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012;119:5972–9
39. F.Müller, N.J.Mutch, W.A.Schenk,. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009;139:1143–56
40. E.M.Conway Reincarnation of ancient links between coagulation and complement. J Thromb Haemost 2015;13:S121–32
41. G.C.White, R.Rompietti Platelet secretion:indiscriminately spewed forth or highly orchestrated? J Thromb Haemost 2007;5:2006–8
42. Q.Ren, S.Ye, S.W.Whiteheart The platelet release reaction:just when you thought platelet secretion was simple. Curr Opin Hematol 2008;15:537–41
43. J.Kamykowski, P.Carlton, S.Sehgal, B.Storrie. Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet α-granules. Blood 2011;118:1370–3
44. M.Cattaneo Inherited platelet-based bleeding disorders. J Thromb Haemost 2003;1:1628–36
45. A.Drouin, R.Favier, J.M.Masse,. Newly recognized cellular abnormalities in the gray platelet syndrome. Blood 2001;98:1382–91
46. W.H.Kahr, J.Hinckley, L.Li,. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet 2011;43:738–40
47. P.B.Tracy, A.R.Giles, K.G.Mann,. Factor V (Quebec):a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984;74:1221–8
48. P.Blair, R.Flaumenhaft Platelet alpha-granules:basic biology and clinical correlates. Blood Rev 2009;23:177–89
49. H.Ni, J.M.Papalia, J.L.Degen, D.D.Wagner Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 2003;102:3609–14
50. Z.Zhai, J.Wu, X.Xu,. Fibrinogen controls human platelet fibronectin internalization and cell-surface retention. J Thromb Haemost 2007;5:1740–6
51. K.R.Machlus, J.E.Italiano, Jr. The incredible journey:from megakaryocyte development to platelet formation. J Cell Biol 2013;201:785–96
52. A.S.Weyrich, H.Schwertz, L.W.Kraiss, G.A.Zimmerman Protein synthesis by platelets:historical and new perspectives. J Thromb Haemost 2009;7:241–6
53. H.Yang, S.Lang, Z.Zhai,. Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood 2009;114:425–36
54. H.Schwertz, G.A.Zimmerman, A.S.Weyrich Fibrinogen selects selectins. Blood 2009;114:234
55. H.Schwertz, S.Koster, W.H.Kahr,. Anucleate platelets generate progeny. Blood 2010;115:3801–9
56. G.A.Zimmerman, A.S.Weyrich Signal-dependent protein synthesis by activated platelets:new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008;28:s17–24
57. M.M.Denis, N.D.Tolley, M.Bunting,. Escaping the nuclear confines:signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005;122:379–91
58. A.S.Weyrich, M.M.Denis, H.Schwertz,. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007;109:1975–83
59. O.Panes, V.Matus, C.G.Saez,. Human platelets synthesize and express functional tissue factor. Blood 2007;109:5242–50
60. H.Brogren, L.Karlsson, M.Andersson,. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004;104:3943–8
61. V.Evangelista, S.Manarini, A.Di Santo,. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006;98:593–5
62. M.C.Berndt, D.Karunakaran, E.E.Gardiner, R.K.Andrews Programmed autologous cleavage of platelet receptors. J Thromb Haemost 2007;5:212–19
63. K.P.Fong, C.Barry, A.N.Tran,. Deciphering the human platelet sheddome. Blood 2011;117:e15–26
64. W.Bergmeier, T.Rabie, A.Strehl,. GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost 2004;91:951–8
65. W.Bergmeier, C.L.Piffath, G.Cheng,. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 2004;95:677–83
66. A.Facey, I.Pinar, J.F.Arthur,. A-Disintegrin-And-Metalloproteinase (ADAM) 10 activity on resting and activated platelets. Biochemistry 2016;55:1187–94
67. R.Zonneveld, R.Martinelli, N.I.Shapiro,. Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care 2014;18:204
68. V.S.Dole, W.Bergmeier, I.S.Patten,. PSGL-1 regulates platelet P-selectin-mediated endothelial activation and shedding of P-selectin from activated platelets. Thromb Haemost 2007;98:806–12
69. K.R.Machlus, J.N.Thon, J.E.Italiano, Jr. Interpreting the developmental dance of the megakaryocyte:a review of the cellular and molecular processes mediating platelet formation. Br J Haematol 2014;165:227–36
70. T.Junt, H.Schulze, Z.Chen,. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007;317:1767–70
71. Y.Wang, V.Hayes, D.Jarocha,. Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice:a cautionary tale. Blood 2015;125:3627–36
72. R.Fuentes, Y.Wang, J.Hirsch,. Infusion of mature megakaryocytes into mice yields functional platelets. J Clin Invest 2010;120:3917–22
73. Y.Hou, N.Carrim, Y.Wang,. Platelets in hemostasis and thrombosis:novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. J Biomed Res 2015;29:437–44
74. K.Kaushansky Thrombopoiesis. Semin Hematol 2015;52:4–11
75. D.J.Kuter Milestones in understanding platelet production:a historical overview. Br J Haematol 2014;165:248–58
76. D.J.Kuter The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013;98:10–23
77. J.B.Bussel, D.J.Kuter, L.M.Aledort,. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 2014;123:3887–94
78. S.Nishimura, M.Nagasaki, S.Kunishima,. IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol 2015;209:453–66
79. J.E.Italiano, J.H.Hartwig Chapter 2:megakaryocyte development and platelet formation. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013:27–49
80. A.Balduini, C.A.Di Buduo, D.L.Kaplan Translational approaches to functional platelet production ex vivo. Thromb Haemost 2015;115:250–6
81. M.Xu, L.Ma, N.Carrim,. Platelet GPIba is important for thrombopoietin production and thrombopoietin-induced platelet generation. Blood 2015;126:12
82. B.T.Kile The role of apoptosis in megakaryocytes and platelets. Br J Haematol 2014;165:217–26
83. V.Leytin Apoptosis in the anucleate platelet. Blood Rev 2012;26:51–63
84. V.Leytin, S.Mykhaylov, A.F.Starkey,. Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 2006;133:78–82
85. B.Nieswandt, W.Bergmeier, K.Rackebrandt,. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000;96:2520–7
86. J.Li, D.E.van der Wal, L.Zhu,. Fc-independent phagocytosis:implications for IVIG and other therapies in immune-mediated thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 2013;13:50–8
87. R.Grozovsky, S.Giannini, H.Falet, K.M.Hoffmeister Regulating billions of blood platelets:glycans and beyond. Blood 2015;126:1877–84
88. K.D.Mason, M.R.Carpinelli, J.I.Fletcher,. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173–86
89. N.Maugeri, P.Rovere-Querini, V.Evangelista,. Neutrophils phagocytose activated platelets in vivo:a phosphatidylserine, P-selectin, and {beta}2 integrin-dependent cell clearance program. Blood 2009;113:5254–65
90. M.Miyanishi, K.Tada, M.Koike,. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007;450:435–9
91. M.L.Rand, H.Wang, K.W.Bang,. Rapid clearance of procoagulant platelet-derived microparticles from the circulation of rabbits. J Thromb Haemost 2006;4:1621–3
92. J.Li, D.E.van der Wal, G.Zhu,. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015;6:7737
93. A.J.Jansen, J.Peng, H.G.Zhao,. Sialidase inhibition to increase platelet counts:a new treatment option for thrombocytopenia. Am J Hematol 2015;90:E94–5
94. P.K.Grewal, S.Uchiyama, D.Ditto,. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008;14:648–55
95. V.Rumjantseva, P.K.Grewal, H.H.Wandall,. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009;15:1273–80
96. R.Grozovsky, A.J.Begonja, K.Liu,. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2015;21:47–54
97. D.van der Wal, G.Zhu, J.Li,. Desialylation:a novel platelet clearance mechanism and a potential new therapeutic target in anti-GPIb antibody mediated thrombocytopenia. Blood 2012;120:265
98. R.McMillan Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am 2009;23:1163–75
99. D.B.Cines, A.Cuker, J.W.Semple Pathogenesis of immune thrombocytopenia. Presse Med 2014;43:e49–59
100. C.Kaplan, H.Ni, J.Freedman Chapter 46:alloimmune thrombocytopenia. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013:953–70
101. J.Bussel Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost 2009;7:253–7
102. X.R.Xu, R.C.Gallant, H.Ni Platelets, immune-mediated thrombocytopenias, and fetal hemorrhage. Thromb Res 2016;141:S76–79
103. W.J.Harrington, V.Minnich, J.W.Hollingsworth, C.V.Moore Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1–10
104. H.Zhou, Y.Hou, X.Liu,. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia. Thromb Haemost 2015;113:1021–34
105. M.L.Webster, E.Sayeh, M.Crow,. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006;108:943–6
106. M.L.Webster, G.Zhu, Y.Li, H.Ni Fc-independent phagocytosis:implications for intravenous IgG therapy in immune thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 2008;8:278–82
107. Q.Zeng, L.Zhu, L.Tao,. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol 2012;87:206–8
108. T.Nishimoto, T.Satoh, E.K.Simpson,. Predominant autoantibody response to GPIb/IX in a regulatory T-cell-deficient mouse model for immune thrombocytopenia. J Thromb Haemost 2013;11:369–72
109. D.S.Beardsley, M.Ertem Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci 1998;19:237–44
110. R.McMillan Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura:assays and epitopes. J Pediatr Hematol Oncol 2003;25:S57–61
111. A.R.Crow, A.H.Lazarus Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25:S14–18
112. V.Siragam, A.R.Crow, D.Brinc,. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006;12:688–92
113. J.Peng, S.H.Ma, J.Liu,. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia:a multicenter cohort study. J Thromb Haemost 2014;12:497–504
114. R.S.Go, K.L.Johnston, K.C.Bruden The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 2007;92:283–4
115. C.Li, S.Piran, P.Chen,. The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011;121:4537–47
116. J.Li, J.L.Callum, Y.Lin,. Severe platelet desialylation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica 2014;99:e61–3
117. L.Shao, Y.Wu, H.Zhou,. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets 2015;26:495–7
118. B.Olsson, P.O.Andersson, M.Jernas,. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123–4
119. L.Chow, R.Aslam, E.R.Speck,. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 2010;115:1247–53
120. L.Guo, R.Kapur, R.Aslam,. CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia Blood 2015;127:735–8
121. K.Yazdanbakhsh, H.Zhong, W.Bao Immune dysregulation in immune thrombocytopenia (ITP). Semin Hematol 2013;50:S63–7
122. R.Aslam, Y.Hu, S.Gebremeskel,. Thymic retention of CD4 + CD25 + FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood 2012;120:2127–32
123. L.Ma, E.Simpson, J.Li,. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood 2015;126:247–56
124. C.Kaplan Foetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Dis 2006;1:39
125. D.Zdravic, I.Yougbare, B.Vadasz,. Fetal and neonatal alloimmune thrombocytopenia. Semin Fetal Neonatal Med 2016;21:19–27
126. H.Tiller, M.K.Killie, P.Chen,. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia:induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion 2012;52:1446–57
127. V.M.Serrarens-Janssen, B.A.Semmekrot, V.M.Novotny,. Fetal/neonatal allo-immune thrombocytopenia (FNAIT):past, present, and future. Obstet Gynecol Surv 2008;63:239–52
128. B.Vadasz, P.Chen, I.Yougbaré,. Platelets and platelet alloantigens:lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia. Genes Dis 2015;2:173–85
129. H.Tiller, M.K.Killie, A.Husebekk,. Platelet antibodies and fetal growth:maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta bstetricia Obstet Gynecol Scand 2012;91:79–86
130. P.Chen, C.Li, S.Lang,. Animal model of fetal and neonatal immune thrombocytopenia:role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010;116:3660–8
131. H.Ni, P.Chen, C.M.Spring,. A novel murine model of fetal and neonatal alloimmune thrombocytopenia:response to intravenous IgG therapy. Blood 2006;107:2976–83
132. C.Li, P.Chen, B.Vadasz,. Co-stimulation with LPS or Poly I:C markedly enhances the anti-platelet immune response and severity of fetal and neonatal alloimmune thrombocytopenia. Thromb Haemost 2013;110:1250–8
133. I.Yougbare, D.Zdravic, H.Ni Angiogenesis and bleeding disorders in FNAIT. Oncotarget 2015;6:15724–5
134. L.J.Butros, J.B.Bussel Intracranial hemorrhage in immune thrombocytopenic purpura:a retrospective analysis. J Pediatr Hematol Oncol 2003;25:660–4
135. N.Mackman Triggers, targets and treatments for thrombosis. Nature 2008;451:914–18
136. H.Ni, C.V.Denis, S.Subbarao,. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000;106:385–92
137. S.Kulkarni, S.M.Dopheide, C.L.Yap,. A revised model of platelet aggregation. J Clin Invest 2000;105:783–91
138. S.Falati, P.Gross, G.Merrill-Skoloff,. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002;8:1175–81
139. U.J.Sachs, B.Nieswandt In vivo thrombus formation in murine models. Circ Res 2007;100:979–91
140. R.Flaumenhaft Thrombus formation reimagined. Blood 2014;124:1697–8
141. K.J.Clemetson, J.M.Clemetson Chapter 9:platelet Receptors. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013:169–94
142. H.Ni, J.Freedman Platelets in hemostasis and thrombosis:role of integrins and their ligands. Transfus Apher Sci 2003;28:257–64
143. W.Bergmeier, R.O.Hynes Extracellular matrix proteins in hemostasis and thrombosis. Cold Spring Harb Perspect Biol 2012;4:a005132
144. S.Patel, Y.W.Huang, A.Reheman,. The cell motility modulator Slit2 is a potent inhibitor of platelet function. Circulation 2012;126:1385–95
145. A.C.Vendrig, A.Reheman, M.A.Siraj,. Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis. Diabetes 2016; 65:1714–23
146. J.Crockett, D.K.Newman, P.J.Newman PECAM-1 functions as a negative regulator of laminin-induced platelet activation. J Thromb Haemost 2010;8:1584–93
147. B.E.Tourdot, M.K.Brenner, K.C.Keough,. Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases:a case study involving PECAM-1. Biochemistry 2013;52:2597–608
148. C.Wong, Y.Liu, J.Yip,. CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo. Blood 2009;113:1818–28
149. J.A.Lopez, R.K.Andrews, V.Afshar-Kharghan, M.C.Berndt Bernard-Soulier syndrome. Blood 1998;91:4397–418
150. A.T.Nurden Platelet membrane glycoproteins:a historical review. Semin Thromb Hemost 2014;40:577–84
151. B.M.Ewenstein Von Willebrand's disease. Annu Rev Med 1997;48:525–42
152. J.Martinez Congenital dysfibrinogenemia. Curr Opin Hematol 1997;4:357–65
153. X.Xu, J.Wu, Z.Zhai,. A novel fibrinogen Bbeta chain frameshift mutation in a patient with severe congenital hypofibrinogenaemia. Thromb Haemost 2006;95:931–5
154. Z.M.Ruggeri, S.P.Jackson Chapter 20:platelet thrombus formation in flowing blood. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013;399–424
155. S.P.Jackson The growing complexity of platelet aggregation. Blood 2007;109:5087–95
156. J.A.Lopez, J.F.Dong Structure and function of the glycoprotein Ib-IX-V complex. Curr Opin Hematol 1997;4:323–9
157. S.Z.Luo, X.Mo, V.Afshar-Kharghan,. Glycoprotein Ibalpha forms disulfide bonds with 2 glycoprotein Ibbeta subunits in the resting platelet. Blood 2007;109:603–9
158. L.Zhou, W.Yang, R.Li Analysis of inter-subunit contacts reveals the structural malleability of extracellular domains in platelet glycoprotein Ib-IX complex. J Thromb Haemost 2014;12:82–9
159. H.Ni, V.Ramakrishnan, Z.M.Ruggeri,. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V. Blood 2001;98:368–73
160. S.Moog, P.Mangin, N.Lenain,. Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood 2001;98:1038–46
161. V.Ramakrishnan, F.DeGuzman, M.Bao,. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci USA 2001;98:1823–8
162. B.Nieswandt, C.Brakebusch, W.Bergmeier,. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 2001;20:2120–30
163. R.H.Lee, W.Bergmeier Platelet immunoreceptor tyrosine-based activation motif (ITAM) and hemITAM signaling and vascular integrity in inflammation and development. J Thromb Haemost 2016;14:645–54
164. J.Gibbins, J.Asselin, R.Farndale,. Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets. J Biol Chem 1996;271:18095–9
165. A.Poole, J.M.Gibbins, M.Turner,. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997;16:2333–41
166. F.Yanaga, A.Poole, J.Asselin,. Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor. Biochem J 1995;311:471–8
167. B.Nieswandt, S.P.Watson Platelet-collagen interaction:is GPVI the central receptor? Blood 2003;102:449–61
168. D.Varga-Szabo, I.Pleines, B.Nieswandt Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008;28:403–12
169. S.A.Santoro, M.M.Zutter The alpha 2 beta 1 integrin:a collagen receptor on platelets and other cells. Thromb Haemost 1995;74:813–21
170. M.Mazzucato, M.R.Cozzi, M.Battiston,. Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow. Blood 2009;114:2793–801
171. B.Savage, F.Almus-Jacobs, Z.M.Ruggeri Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998;94:657–66
172. B.Savage, E.Saldivar, Z.M.Ruggeri Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996;84:289–97
173. M.Mazzucato, P.Pradella, M.R.Cozzi,. Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor. Blood 2002;100:2793–800
174. Y.S.Bynagari-Settipalli, I.Cornelissen, D.Palmer,. Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. Arterioscler Thromb Vasc Biol 2014;34:2563–9
175. L.F.Brass, D.K.Newman, K.M.Wannemacher, T.J.Stalker Chapter 19:signal transduction during platelet plug formation. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013:367–98
176. K.J.Clemetson Snaclecs (snake C-type lectins) that inhibit or activate platelets by binding to receptors. Toxicon 2010;56:1236–46
177. X.Lei, A.Reheman, Y.Hou,. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014;111:279–89
178. B.Li, X.Dai, Z.Yang,. First ex vivo and in vivo assessment of anfibatide, a novel glycoprotein Ib-IV-V complex antagonist, in healthy human volunteers in phase I clinical trial. J Thromb Haemost 2013;11:23
179. Y.Hou, B.X.Li, X.Dai,. The first in vitro and in vivo assessment of anfibatide, a novel glycoprotein ib antagonist, in mice and in a phase i human clinical trial. Blood 2013;122:577
180. P.Metharom, M.C.Berndt, R.I.Baker, R.K.Andrews Current state and novel approaches of antiplatelet therapy. Arterioscler Thromb Vasc Biol 2015;35:1327–38
181. T.Xiao, J.Takagi, B.S.Coller,. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004;432:59–67
182. B.Savage, M.Cattaneo, Z.M.Ruggeri Mechanisms of platelet aggregation. Curr Opin Hematol 2001;8:270–6
183. J.Ware, S.Russell, Z.M.Ruggeri Generation and rescue of a murine model of platelet dysfunction:the Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000;97:2803–8
184. B.S.Coller Platelet GPIIb/IIIa antagonists:the first anti-integrin receptor therapeutics. J Clin Invest 1997;99:1467–71
185. R.M.Scarborough, N.S.Kleiman, D.R.Phillips Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437–44
186. K.M.Brinkhous, R.G.Mason Fibrinogen:requirement for platelet aggregation and adhesion. Acta Univ Carol Med Monogr 1972;53:9–16
187. H.Yang, A.Reheman, P.Chen,. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 2006;4:2230–7
188. A.Reheman, H.Yang, G.Zhu,. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2009;113:1809–17
189. M.Jirouskova, I.Chereshnev, H.Vaananen,. Antibody blockade or mutation of the fibrinogen gamma-chain C-terminus is more effective in inhibiting murine arterial thrombus formation than complete absence of fibrinogen. Blood 2004;103:1995–2002
190. Y.Wang, A.Reheman, C.M.Spring,. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest 2014;124:4281–93
191. H.Ni, A.Li, N.Simonsen, J.A.Wilkins Integrin activation by dithiothreitol or Mn2+ induces a ligand-occupied conformation and exposure of a novel NH2-terminal regulatory site on the beta1 integrin chain. J Biol Chem 1998;273:7981–7
192. J.W.Smith, H.Le Calvez, L.Parra-Gessert,. Selection and structure of ion-selective ligands for platelet integrin alpha IIb(beta) 3. J Biol Chem 2002;277:10298–305
193. R.O.Hynes Integrins:bidirectional, allosteric signaling machines. Cell 2002;110:673–87
194. B.H.Luo, C.V.Carman, T.A.Springer Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007;25:619–47
195. H.Ni, J.A.Wilkins Localisation of a novel adhesion blocking epitope on the human beta 1 integrin chain. Cell Adhes Commun 1998;5:257–71
196. Y.Mou, H.Ni, J.A.Wilkins The selective inhibition of beta 1 and beta 7 integrin-mediated lymphocyte adhesion by bacitracin. J Immunol 1998;161:6323–9
197. S.Tsuji, M.Sugimoto, S.Miyata,. Real-time analysis of mural thrombus formation in various platelet aggregation disorders:distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 1999;94:968–75
198. H.Ni, P.S.Yuen, J.M.Papalia,. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci USA 2003;100:2415–19
199. H.Ni Unveiling the new face of fibronectin in thrombosis and hemostasis. J Thromb Haemost 2006;4:940–2
200. Y.Wang, H.Ni Fibronectin maintains the balance between hemostasis and thrombosis. Cell Mol Life Sci 2016. [Epub ahead of print]. doi:10.1007/s00018-016-2225-y
201. Y.Wang, N.Carrim, H.Ni Fibronectin orchestrates thrombosis and hemostasis. Oncotarget 2015;6:19350–1
202. P.S.Frenette, D.D.Wagner Adhesion molecules–part II:blood vessels and blood cells. N Engl J Med 1996;335:43–5
203. Y.Wang, H.Ni Fibronectin:extra domain brings extra risk? Blood 2015;125:3043–4
204. J.W.Eikelboom, D.J.Quinlan, J.van Ryn, J.I.Weitz Idarucizumab:the antidote for reversal of dabigatran. Circulation 2015;132:2412–22
205. L.J.Eltringham-Smith, X.Lei, A.Reheman,. The fibrinogen but not the Factor VIII content of transfused plasma determines its effectiveness at reducing bleeding in coagulopathic mice. Transfusion 2015;55:1040–50
206. A.Bonnefoy, K.Daenens, H.B.Feys,. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub) endothelial VWF from cleavage by ADAMTS13. Blood 2006;107:955–64
207. P.Prakash, P.P.Kulkarni, A.K.Chauhan Thrombospondin 1 requires von Willebrand factor to modulate arterial thrombosis in mice. Blood 2015;125:399–406
208. E.Dunne, C.M.Spring, A.Reheman,. Cadherin 6 has a functional role in platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 2012;32:1724–31
209. B.A.Bouchard, J.R.Silveira, P.B.Tracy Chapter 21:interactions between platelets and the coagulation system. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013:425–52
210. T.Gui, A.Reheman, W.K.Funkhouser,. In vivo response to vascular injury in the absence of factor IX:examination in factor IX knockout mice. Thromb Res 2007;121:225–34
211. T.Gui, A.Reheman, H.Ni,. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost 2009;7:1843–51
212. J.Suzuki, M.Umeda, P.J.Sims, S.Nagata Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010;468:834–8
213. R.F.Zwaal, P.Comfurius, E.M.Bevers Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochimica Et Biophysica Acta 2004;1636:119–28
214. S.R.Coughlin Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005;3:1800–14
215. A.Reheman, X.Xu, E.C.Reddy, H.Ni Targeting activated platelets and fibrinolysis:hitting two birds with one stone. Circ Res 2014;114:1070–3
216. D.Mozaffarian, E.J.Benjamin, A.S.Go,. Heart disease and stroke statistics-2016 update:a report from the american heart association. Circulation 2016;133:e38–e360
217. B.Furie, B.C.Furie Mechanisms of thrombus formation. N Engl J Med 2008;359:938–49
218. T.Palabrica, R.Lobb, B.C.Furie,. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992;359:848–51
219. S.Falati, Q.Liu, P.Gross,. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585–98
220. J.Chou, N.Mackman, G.Merrill-Skoloff,. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004;104:3190–7
221. J.Polgar, J.Matuskova, D.D.Wagner The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005;3:1590–6
222. I.Hrachovinova, B.Cambien, A.Hafezi-Moghadam,. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003;9:1020–5
223. C.Reinhardt, M.L.von Bruhl, D.Manukyan,. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008;118:1110–22
224. N.Carrim, G.Zhu, E.C.Reddy,. Integrin PSI domain has endogenous thiol isomerase function and is a novel target for anti-thrombotic therapy. J Thromb Haemost 2015;13:60
225. P.Andre, K.S.Prasad, C.V.Denis,. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002;8:247–52
226. P.Jilma-Stohlawetz, M.E.Gorczyca, B.Jilma,. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011;105:545–52
227. M.Ungerer, K.Rosport, A.Bultmann,. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011;123:1891–9
228. A.GmbH. Revacept in symptomatic carotid stenosis (Revacept/CS/02). [Online]. Available from:http://clinicaltrials.gov/ct2/show/NCT01645306 [last accessed 9 Jun, 2016]
229. R.C.Becker, D.J.Moliterno, L.K.Jennings,. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention:a randomised, double-blind, placebo-controlled phase II study. Lancet 2009;373:919–28
230. V.L.Serebruany, S.D.Fortmann The FDA report on vorapaxar in the elderly:a convoluted dilemma. Int J Cardiol 2015;201:601–3
231. C.L.Fanola Current and emerging strategies in the management of venous thromboembolism:benefit-risk assessment of dabigatran. Vasc Health Risk Manag 2015;11:271–82
232. M.M.Aleman, B.L.Walton, J.R.Byrnes, A.S.Wolberg Fibrinogen and red blood cells in venous thrombosis. Thromb Res 2014;133:S38–40
233. S.Sevitt The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol 1974;27:517–28
234. B.Engelmann, S.Massberg Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13:34–45
235. A.Brill, T.A.Fuchs, A.K.Chauhan,. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011;117:1400–7
236. M.L.Von Bruhl, K.Stark, A.Steinhart,. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209:819–35
237. N.Maugeri, M.Brambilla, M.Camera,. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost 2006;4:1323–30
238. A.S.Wolberg, D.M.Monroe, H.R.Roberts, M.R.Hoffman Tissue factor de-encryption:ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis 1999;10:201–10
239. A.Brill, T.A.Fuchs, A.S.Savchenko,. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012;10:136–44
240. T.A.Fuchs, A.Brill, D.Duerschmied,. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010;107:15880–5
241. T.A.Fuchs, A.A.Bhandari, D.D.Wagner Histones induce rapid and profound thrombocytopenia in mice. Blood 2011;118:3708–14
242. F.Semeraro, C.T.Ammollo, J.H.Morrissey,. Extracellular histones promote thrombin generation through platelet-dependent mechanisms:involvement of platelet TLR2 and TLR4. Blood 2011;118:1952–61
243. T.A.Fuchs, A.Brill, D.D.Wagner Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1777–83
244. P.E.Rautou, N.Mackman Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol 2013;6:91–101
245. N.Mackman Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis 2006;36:104–7
246. L.A.Castellucci, C.Cameron, G.Le Gal,. Clinical and safety outcomes associated with treatment of acute venous thromboembolism:a systematic review and meta-analysis. JAMA 2014;312:1122–35
247. M.Sharma, V.R.Cornelius, J.P.Patel,. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism:systematic review and meta-analysis. Circulation 2015;132:194–204
248. Y.H.Mekaj, F.T.Daci, A.Y.Mekaj New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag 2015;11:1449–56
249. C.Becattini, G.Agnelli Aspirin for prevention and treatment of venous thromboembolism. Blood Rev 2014;28:103–8
250. V.Brinkmann, U.Reichard, C.Goosmann,. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532–5
251. A.S.Savchenko, J.I.Borissoff, K.Martinod,. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood 2014;123:141–8
252. B.J.McMorran, V.M.Marshall, C.de Graaf,. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science 2009;323:797–800
253. B.J.McMorran, L.Wieczorski, K.E.Drysdale,. Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science 2012;338:1348–51
254. R.Aslam, E.R.Speck, M.Kim,. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006;107:637–41
255. G.Zhang, J.Han, E.J.Welch,. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 2009;182:7997–8004
256. S.R.Clark, A.C.Ma, S.A.Tavener,. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007;13:463–9
257. W.S.Alexander, A.W.Roberts, N.A.Nicola,. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996;87:2162–70
258. M.Norgaard, A.O.Jensen, M.C.Engebjerg,. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia:a Danish population-based cohort study. Blood 2011;117:3514–20
259. S.W.Kerrigan, I.Douglas, A.Wray,. A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. Blood 2002;100:509–16
260. D.O.Tilley, M.Arman, A.Smolenski,. Glycoprotein Ibalpha and FcgammaRIIa play key roles in platelet activation by the colonizing bacterium, Streptococcus oralis. J Thromb Haemost 2013;11:941–50
261. C.Chaipan, E.J.Soilleux, P.Simpson,. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol 2006;80:8951–60
262. A.Y.Simon, M.R.Sutherland, E.L.Pryzdial Dengue virus binding and replication by platelets. Blood 2015;126:378–85
263. P.E.Stenberg, R.P.McEver, M.A.Shuman,. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880–6
264. R.Bonfanti, B.C.Furie, B.Furie, D.D.Wagner PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989;73:1109–12
265. J.Yang, B.C.Furie, B.Furie The biology of P-selectin glycoprotein ligand-1:its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999;81:1–7
266. D.I.Simon, Z.Chen, H.Xu,. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000;192:193–204
267. T.N.Mayadas, R.C.Johnson, H.Rayburn,. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993;74:541–54
268. M.Chen, J.G.Geng P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 2006;54:75–84
269. C.Cerletti, C.Tamburrelli, B.Izzi,. Platelet-leukocyte interactions in thrombosis. Thromb Res 2012;129:263–6
270. M.Ghasemzadeh, E.Hosseini Platelet-leukocyte crosstalk:linking proinflammatory responses to procoagulant state. Thromb Res 2013;131:191–7
271. B.Felding-Habermann, T.E.O'Toole, J.W.Smith,. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001;98:1853–8
272. T.J.Gould, Z.Lysov, P.C.Liaw Extracellular DNA and histones:double-edged swords in immunothrombosis. J Thromb Haemost 2015;13:S82–91
273. K.Martinod, D.D.Wagner Thrombosis:tangled up in NETs. Blood 2014;123:2768–76
274. S.Massberg, L.Grahl, M.L.von Bruehl,. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010;16:887–96
275. T.G.Diacovo, K.D.Puri, R.A.Warnock,. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996;273:252–5
276. D.Vestweber, M.K.Wild A new player in lymphocyte homing. Nat Immunol 2008;9:347–8
277. C.Scheiermann, P.S.Frenette, A.Hidalgo Regulation of leucocyte homeostasis in the circulation. Cardiovasc Res 2015;107:340–51
278. B.D.Elzey, J.Tian, R.J.Jensen,. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003;19:9–19
279. B.D.Elzey, J.F.Grant, H.W.Sinn,. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukoc Biol 2005;78:80–4
280. G.Shi, D.J.Field, K.A.Ko,. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. J Clin Invest 2014;124:543–52
281. J.Ahamed, N.Burg, K.Yoshinaga,. In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1. Blood 2008;112:3650–60
282. D.D.McManus, J.E.Freedman MicroRNAs in platelet function and cardiovascular disease. Nat Rev Cardiol 2015;12:711–17
283. V.Henn, J.R.Slupsky, M.Grafe,. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–4
284. M.Sadowski, M.Zabczyk, A.Undas Coronary thrombus composition:links with inflammation, platelet and endothelial markers. Atherosclerosis 2014;237:555–61
285. F.Langer, S.B.Ingersoll, A.Amirkhosravi,. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost 2005;93:1137–46
286. S.Badrnya, W.C.Schrottmaier, J.B.Kral,. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscler Thromb Vasc Biol 2014;34:571–80
287. C.A.Gleissner Platelet-derived chemokines in atherogenesis:what's new? Curr Vasc Pharmacol 2012;10:563–9
288. C.K.Glass, J.L.Witztum Atherosclerosis. the road ahead. Cell 2001;104:503–16
289. X.Zhou, G.Paulsson, S.Stemme, G.K.Hansson Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998;101:1717–25
290. F.Austrup, D.Vestweber, E.Borges,. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997;385:81–3
291. Z.M.Dong, S.M.Chapman, A.A.Brown,. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998;102:145–52
292. Z.M.Dong, A.A.Brown, D.D.Wagner Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000;101:2290–5
293. P.C.Burger, D.D.Wagner Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101:2661–6
294. E.A.Podrez, T.V.Byzova, M.Febbraio,. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007;13:1086–95
295. H.Ni The platelet in diabetes. Blood 2012;119:5949–51
296. M.Valiyaveettil, N.Kar, M.Z.Ashraf,. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 2008;111:1962–71
297. Y.Yang, M.C.Andrews, Y.Hu,. Anthocyanin extract from black rice significantly ameliorates platelet hyperactivity and hypertriglyceridemia in dyslipidemic rats induced by high fat diets. J Agric Food Chem 2011;59:6759–64
298. Y.Yang, Z.Shi, A.Reheman,. Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis:novel protective roles against cardiovascular diseases. PloS One 2012;7:e37323
299. F.Song, Y.Zhu, Z.Shi,. Plant food anthocyanins inhibit platelet granule secretion in hypercholesterolaemia:involving the signalling pathway of PI3K-Akt. Thromb Haemost 2014;112:981–91
300. S.Ciatto, D.Ambrogetti, R.Bonardi,. Prognostic impact of early detection of contralateral primary breast cancer. Tumori 1990;76:370–3
301. P.Uhrin, J.Zaujec, J.M.Breuss,. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood 2010;115:3997–4005
302. L.Carramolino, J.Fuentes, C.Garcia-Andres,. Platelets play an essential role in separating the blood and lymphatic vasculatures during embryonic angiogenesis. Circ Res 2010;106:1197–201
303. C.C.Bertozzi, A.A.Schmaier, P.Mericko,. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010;116:661–70
304. B.A.Finney, E.Schweighoffer, L.Navarro-Nunez,. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. Blood 2012;119:1747–56
305. P.Carmeliet, R.K.Jain Angiogenesis in cancer and other diseases. Nature 2000;407:249–57
306. P.Carmeliet Angiogenesis in health and disease. Nat Med 2003;9:653–60
307. T.G.Walsh, P.Metharom, M.C.Berndt The functional role of platelets in the regulation of angiogenesis. Platelets 2015;26:199–211
308. H.Hallberg, B.Mattsson. Premature deaths among men in a Swedish municipality-social characteristics prior to death. Scand J Soc Med 1991;19:181–6
309. E.M.Battinelli, B.A.Markens, J.E.Italiano, Jr. Release of angiogenesis regulatory proteins from platelet alpha granules:modulation of physiologic and pathologic angiogenesis. Blood 2011;118:1359–69
310. H.van Nispen tot Pannerden, F.de Haas, W.Geerts,. The platelet interior revisited:electron tomography reveals tubular alpha-granule subtypes. Blood 2010;116:1147–56
311. P.C.Brooks, A.M.Montgomery, M.Rosenfeld,. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157–64
312. L.E.Reynolds, L.Wyder, J.C.Lively,. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002;8:27–34
313. E.M.Bridges, A.L.Harris The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 2011;81:1183–91
314. R.Kerbel, J.Folkman Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727–39
315. S.Werner, R.Grose Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835–70
316. A.J.Singer, R.A.Clark Cutaneous wound healing. N Engl J Med 1999;341:738–46
317. H.M.Verheul, K.Hoekman, S.Luykx-de Bakker,. Platelet:transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187–90
318. N.M.Pandya, N.S.Dhalla, D.D.Santani. Angiogenesis:a new target for future therapy. Vascul Pharmacol 2006;44:265–74
319. S.Guo, L.A.Dipietro Factors affecting wound healing. J Dent Res 2010;89:219–29
320. J.R.Lieberman, A.Daluiski, T.A.Einhorn The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002;84-A:1032–44
321. T.G.Walsh, P.Metharom, M.C.Berndt The functional role of platelets in the regulation of angiogenesis. Platelets 2014;7104:1–13
322. B.L.Tranum, A.Haut Thrombocytosis:platelet kinetics in neoplasia. J Lab Clin Med 1974;84:615–19
323. G.J.Gasic, T.B.Gasic, C.C.Stewart Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 1968;61:46–52
324. F.Erdemir, M.Kilciler, S.Bedir,. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 2007;79:111–16
325. S.Taucher, A.Salat, M.Gnant,. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003;89:1098–106
326. L.J.Gay, B.Felding-Habermann Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123–34
327. A.Zaslavsky, K.H.Baek, R.C.Lynch,. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 2010;115:4605–13
328. K.Egan, N.Cooke, D.Kenny Living in shear:platelets protect cancer cells from shear induced damage. Clin Exp Metastasis 2014;31:697–704
329. A.Mitrugno, G.W.Tormoen, P.Kuhn, O.J.McCarty The prothrombotic activity of cancer cells in the circulation. Blood Rev 2015;30:11–19
330. L.A.Coupland, C.R.Parish Platelets, selectins, and the control of tumor metastasis. Semin Oncol 2014;41:422–34
331. H.G.Kopp, T.Placke, H.R.Salih Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009;69:7775–83
332. T.Placke, M.Orgel, M.Schaller,. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res 2012;72:440–8
333. T.Placke, H.G.Kopp, H.R.Salih The wolf in sheep's clothing:platelet-derived impairs cancer cell recognition by NK cells. Oncoimmunology 2012;1:557–9
334. H.A.Goubran, J.Stakiw, M.Radosevic, T.Burnouf Platelet-cancer interactions. Semin Thromb Hemost 2014;40:296–305
335. A.Amirkhosravi, S.A.Mousa, M.Amaya,. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 2003;90:549–54
336. J.S.Desgrosellier, D.A.Cheresh Integrins in cancer:biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9–22
337. Y.J.Kim, L.Borsig, H.L.Han,. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol 1999;155:461–72
338. B.Lebeau, C.Chastang, J.M.Brechot,. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 1994;74:38–45
339. C.P.Klerk, S.M.Smorenburg, H.M.Otten,. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130–5
340. L.Borsig, R.Wong, J.Feramisco,. Heparin and cancer revisited:mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001;98:3352–7
341. H.Laubli, K.S.Spanaus, L.Borsig Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 2009;114:4583–91
342. B.Z.Qian, J.Li, H.Zhang,. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222–5
343. M.Labelle, S.Begum, R.O.Hynes Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011;20:576–90
344. S.J.Israels Chapter 25:platelet function in the newborn. In:A.D.Michelson, ed. Platelets. 3rd ed. Amsterdam:Academic Press/Elsevier, 2013:503–16
345. Z.J.Liu, K.M.Hoffmeister, Z.Hu,. Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood 2014;123:3381–9
346. S.Dayal, K.M.Wilson, D.G.Motto,. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation 2013;127:1308–16
347. M.Lesurtel, R.Graf, B.Aleil,. Platelet-derived serotonin mediates liver regeneration. Science 2006;312:104–7
348. R.Matsuo, Y.Nakano, N.Ohkohchi Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy. Ann Surg 2011;253:759–63